《大行》里昂:药明生物(02269.HK)下半财年纯利远胜预期 续列行业首选

阿斯达克财经
Feb 11

里昂发表研究报告指,药明生物(02269.HK) 就2025年下半年业绩发盈喜,当中收入预计按年增长17%,大致符合预期,而纯利按年升38%至26亿元人民币;经调整纯利增31%至37亿元人民币,均远胜市场预期。另外,毛利率按年增6.2个百分点至48.8%,属是次盈喜中的核心利好惊喜,亦是盈利表现胜预期的主要驱动力。该行表示,在中国的医药合约研发机构(CRO)和医药合同研发生产机构(CDMO)行业中...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10